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Maternal exposure to the neurotoxin methylmercury (MeHg) 
has been shown to have adverse effects on neural development of 
the offspring in man. Little is known about the underlying mech-
anisms by which MeHg affects the developing brain. To explore 
the neurodevelopmental defects and the underlying mechanism 
associated with MeHg exposure, the cerebellum and cerebrum of 
Wistar rat pups were analyzed by [18F]FDG PET functional imag-
ing, field potential analysis, and microarray gene expression pro-
filing. Female rat pups were exposed to MeHg via maternal diet 
during intrauterinal and lactational period (from gestational day 
6 to postnatal day (PND)10), and their brain tissues were sampled 
for the analysis at weaning (PND18–21) and adulthood (PND61–
70). The [18F]FDG PET imaging and field potential analysis sug-
gested a delay in brain activity and impaired neural function by 
MeHg. Genome-wide transcriptome analysis substantiated these 
findings by showing (1) a delay in the onset of gene expression 
related to neural development, and (2) alterations in pathways 
related to both structural and functional aspects of nervous sys-
tem development. The latter included changes in gene expression 
of developmental regulators, developmental phase–associated 
genes, small GTPase signaling molecules, and representatives of 
all processes required for synaptic transmission. These findings 
were observed at dose levels at which only marginal changes in 
conventional developmental toxicity endpoints were detected. 
Therefore, the approaches applied in this study are promising in 
terms of yielding increased sensitivity compared with classical 
developmental toxicity tests.
Keywords: neurodevelopment; methylmercury; [18F]FDG 
PET functional imaging; field potential analysis; microarrays; 
neurotoxicity.
The development of the brain is a highly complex and pre-
cisely timed process, which starts at gestation and continues 
throughout juvenile stages to adolescence. The early exposure 
of fetal and juvenile brain to environmental hazards may have 
deleterious effect on its development. Methylmercury (MeHg), 
which is found in some fish and shellfish, has harmful effects on 
the developing human nervous system. MeHg is the most sta-
ble organic form of mercury, and it has a high bioaccumulation 
potential (Clarkson and Magos, 2006; European Commission, 
2006, 2010). The clinical findings in children exposed to MeHg 
poisonings in Japan (Harada, 1968; Takeuchi, 1985; Takizawa 
and Kitamura, 2001) and Iraq (Bakir et al., 1973) have revealed 
the extreme sensitivity of the developing brain to this com-
pound and have triggered a series of animal studies aiming to 
determine the exact consequences of pre- and perinatal expo-
sure to MeHg (Castoldi et al., 2008). Neurobehavioral effects 
reported include altered motoric function and learning and 
memory disabilities; besides, in vitro studies showed inhibi-
tion of neuronal differentiation of neural stem cells (Johansson 
et al., 2007). Nevertheless, the mechanism of action of MeHg 
is unknown, as are the differences in sensitivity of the various 
brain regions. Elucidation of these aspects would contribute to 
fine tuning of guidelines for developmental neurotoxicity test-
ing and thus optimal protection of the offspring health.
The current guidelines for the assessment of MeHg 
developmental neurotoxicity focus on developmental landmarks 
and behavioral and extensive neuropathological/stereological 
surveys. The classical “No Observed Adverse Effect Level” 
(NOAEL) approach (Crump, 1984; Slob, 2002) aims to identify 
the highest dose level tested without an observed change in the 
(critical) endpoint. However, the fact that no change could be 
(statistically) observed at the NOAEL does not necessarily 
imply that there is no biologically relevant adverse effect present 
(European Food Safety Authority (EFSA), 2009). Previously, 
we have shown that by applying the advanced benchmark 
statistical approach, a significant dose-response effect of MeHg 
exposure can be identified in the conditions where classical 
NOAEL approach fails to detect these effects (Tonk et al., 2010). 
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In another related study with equivalent design, the relevance 
of MeHg effects was shown by neuron counting method, which 
detected statistically significant neuron loss at both juvenile 
and adult stage of MeHg-exposed rat pups. In the same study, 
the conventional neuropathological and behavioral guideline 
tests for developmental neurotoxicity (U.S. Environmental 
Protection Agency (U.S. EPA), 1996, 1998; Organisation for 
Economic Co-operation and Development (OECD), 2007) 
showed no statistically significant results (de Groot, personal 
communication). These observations demonstrate that 
conventional animal-based developmental neurotoxicity testing 
methods need to be complemented with more sensitive assays 
in order to accurately predict hazard and ultimately risk in man.
In this study, we investigate the early (lactation and wean-
ing) and the late (adulthood) effects of pre- and perinatal MeHg 
exposure on structural and functional parameters of developing 
rat brain (cerebrum and cerebellum) by [18F]FDG PET func-
tional imaging, field potential analysis, and microarray gene 
expression profiling. Exposure equaled pre- and perinatal win-
dow proposed in U.S.-EPA Test Guideline for developmental 
neurotoxicity, i.e., from gestation day 6 (GD6) to postnatal day 
10 (PND10) (U.S. Environmental Protection Agency, 1998). 
MeHg dose of 1.5 mg/kg was assessed in all assays and both 
tissues, and transcriptional profiling of cerebellum was also 
performed at lower MeHg doses (0.1, 0.4, and 1 mg/kg) to test 
the sensitivity of the method. We found a suggestive delay in 
onset of neural development and/or function and uncovered the 
molecular mechanisms underlying these defects. Importantly, 
we found that the early maternal dietary exposure to MeHg 
results in effects that persist to the adult stage of the exposed 
rats. In addition to the health relevance of these findings, our 
results show that methods for assessment of MeHg neurotoxic-
ity used in this study provide an alternative method of superior 
sensitivity to classical toxicity testing protocols.
MaTEriaLs aND METHoDs
Test substance. Methylmercury (MeHg), CAS 115-09-3, was obtained 
from Sigma-Aldrich, Zwijndrecht, The Netherlands.
Animals and animal husbandry. The in-life part of the study was carried 
out at the Animal Facilities of TNO Location Zeist, The Netherlands, as previ-
ously described (Tonk et al., 2010). Animal care and use were in accordance 
with Directive 86/609/RRC, which established the general principles govern-
ing the use of animals in experiments of the European Communities and with 
Dutch-specific legislation (The Experiments on Animals Act, 1977). Female 
and male Wistar rats (Crl-[WI]-WU BR), purchased from Charles-River 
Germany (Sulzfeld, Germany), were acclimatized for 12 days before mating 
at a ratio of 2 females:1 male. Animals were supplied with RM3 breeding diet 
(SDS, Witham, UK) and tap water, both ad libitum. Animals were housed in 
groups of four per sex in the animal facility with a 12-:12-h light:dark cycle and 
maintained at 22 ± 3°C and 30–70% humidity.
Study design and group selection. A regulatory developmental neuro-
toxicity study was carried out according to test guidelines US EPA OPPTS 
870.6300/8600 (U.S. EPA, 1998). F0 female Wistar rats were orally dosed 
with MeHg dissolved in corn oil (Sigma). The MeHg was administered to the 
dams by gavage between GD6 and lactation day 10 (LD10) in the following 
concentrations: 0, 0.1, 0.4, 0.7, 1.0, 1.5, or 2.0 mg/kg body weight (BW) per 
day. The effects of MeHg on F1 offspring were studied during lactation, wean-
ing, and adulthood by a series of conventional and more advanced tests.
The study started with 15 F0 female rats per group and an additional number 
of 8 females in the control group and also in the 1.5-mg MeHg groups. Per 
group, at least 10 dams with at least 10 pups each were selected for the neuro 
cohort. Litters were culled on PND8 to n = 10 pups/litter (5 male and 5 female 
pups). Two subsets (1 pup/sex/litter; 10 litters/dose group; all groups/subset) 
were selected for conventional behavioral testing and neuropathology as indi-
cated in the test guideline. For PET imaging, five female F1 animals (four and 
a spare rat) from different litters (control group and 1.5-mg MeHg dose group) 
were selected and scanned at PND18, 22, 37, and 61. These time points were 
chosen—as near as possible—as proposed in the test guideline for conven-
tional functional testing, i.e., 13, 17, 21, 61 ± 1 day (functional observational 
battery [FOB] and motor activity assessment [MAA]) but were limited by eth-
ics—no PET scanning allowed below the age of PND17—and logistics—stag-
gered start of experimentation and litters not born on the same day—leading to 
inclusion of PND37 to have another time point during adolescence. Likewise, 
animals for gene expression analysis and field potentials were selected as near 
as possible to weaning (PND21) and young adulthood (PND61 ± 1 day) as pro-
posed for neuropathology survey in the test guideline (see below).
During lactation, developmental parameters (physical/sensory landmarks) 
were measured in both subsets of the neuro cohort, i.e., 2 male and 2 female 
pups/litter; 10 litters/group; all dose groups including control group. All behav-
ioral tests like FOB and MAA (PND13, 17, 21, 61 ± 1 day), auditory startle 
response (PND23 ± 1  day), passive avoidance, and active avoidance tests 
(PND30 and 37 and PND60 and 67 (± 1 day), respectively) were carried out 
with 1 male and 1 female F1 animal/litter; 10 litters per group; all dose groups 
including the control group. Upto PND21, FOB and MAA were carried out in 
both subsets of the neuro cohort.
Subset 1 was sacrificed for neuropathology at PND21; subset 2 at PND70; 
the latter time point was needed to include active avoidance test for cognitive 
functioning (PND60 and 67 (± 1 day). Brains were dissected along neuroana-
tomical landmarks in such a way that left and right hemispheres could be used 
for different purposes (see below section “Brain samples preparation”). As such, 
still 10 animals/sex/group—all from different litters—were sampled for neuro-
pathology (at PND21 and PND70); brain tissues (cerebrum and cerebellum sep-
arately) from at least five female F1 animals from different litters (control group 
and 1.5-mg MeHg group) were sampled for gene expression analysis (“genom-
ics”) during sacrifice (PND21 and PND70). Five female F1 animals from five 
different litters were selected for field potential measurements (control group 
and 1.5-mg MeHg dose group, at PND28 ± 3 days and at PND65 ± 3 days).
Here we report on the assessment of advanced testing technologies, i.e., in 
vivo [18F]FDG PET imaging, ex vivo/in vitro field potential recording in brain 
slabs (hippocampus), and microarray gene expression/pathway analysis (cer-
ebrum, cerebellum). For comparison of relative sensitivity, effects of conven-
tional guideline testing is briefly touched upon (Supplementary material).
The study was accomplished in the spirit of Good Laboratory Practice.
BW and health. BW of the F1 animals was measured at different time 
points during experimentation: twice a week during lactation, starting on PND1 
until PND21 (PND1, 4, 7, 10, 14, 17, and 21); weekly from PND21 onwards. 
Animals were checked daily for clinical signs of adverse effects. In the article, 
only the final outcome of effect of MeHg on BW is given in a brief summariz-
ing table (Supplementary material).
Brain sample preparation. Brains were collected from the female F1 off-
spring immediately after sacrifice. Different brain parts were further dissected 
using neuroanatomical landmarks visible at the outer surface of the brain (de 
Groot et al., 2005a, b). Briefly, one coronal separation was made in between 
the cerebrum and olfactory bulb, and one separation was made in between the 
cerebellum and medulla oblongata/spinal cord at the dorsal end. Subsequently, 
the brain halves were separated along the midline. Then, the cerebrum was sepa-
rated from the cerebellum by a coronal separation perpendicular to the midline. 
All brain parts were measured for size and weighed. Immediately thereafter, 
one brain half—alternating between the left and the right one (the first one was 
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chosen randomly)—was collected in formalin for neuropathology; the other was 
frozen for microarray analysis and toxicokinetic analysis of brain mercury lev-
els. Left and right cerebellar and cerebral regions were also randomly assigned 
to either microarray analysis or toxicokinetic analysis. Frozen samples were 
stored at −80°C until further use. In this article, we only present the microarray 
analysis procedures and results (cerebrum and cerebellum separately).
Conventional neurodevelopmental toxicity testing. The effects on F1 
offspring were studied assessing conventional guideline endpoints (BW, clini-
cal signs, developmental landmarks, neuropathology, and behavior); cerebel-
lar volume and neuron numbers were assessed with stereology as previously 
described (de Groot et  al., 2005a, b). This part of the study is not included 
in this article and will be published elsewhere. However, for comparison of 
the sensitivity of the advanced technologies assessed and described here, the 
final outcome of the conventional tests is given in a brief summarizing table 
(Supplementary material).
[18F]FDG PET imaging. Female rats exposed to 0 (control group, n = 4, 
and a spare animal) or 1.5 mg/kg MeHg daily (MeHg group, n = 4, and a spare 
animal) from GD6 until LD10 were subjected to repeated PET imaging. Brain 
glucose metabolism—a surrogate marker for brain activity—was assessed by 
static [18F]FDG PET imaging on PND18, 22, 37, and 61. One animal in the 
MeHg group died between the third and fourth PET experiment. At the start 
of each PET experiment, the rat was injected ip with 21 ± 3 MBq [18F]FDG. 
Immediately after the tracer injection, the animal was placed in an empty black 
wooden box (1 × 1 × 1 m) that was located in a dark room with monotonous 
background noise. This created circumstances with comparable external stimuli 
in conscious, active animals in which the tracer distribution could take place. 
Forty-five minutes after the administration of [18F]FDG, the animal was taken 
from the box and anesthetized with 5% isoflurane gas in medical air (a mixture 
of 95% O
2
 and 5% CO
2
). The animal was positioned in a small-animal dedicated 
PET camera (Siemens/Concorde MicroPET Focus 220)  with its brain in the 
center of the field of view. At the center of the field of view, the spatial resolu-
tion of the PET camera is 1.35 mm. Anesthesia was maintained with 2% isoflu-
rane in medical air until the end of the PET procedure. A static emission scan 
was performed for 20 min, starting 50 min after tracer injection. Subsequently, a 
transmission scan was performed using an external 57Co point source. The trans-
mission scan lasted 515 s and was used for correction for attenuation and scatter 
of radiation by the tissue within the animal and the camera bed. After comple-
tion of the transmission scan, the animals were placed back into their cages to 
recover. Animals from the MeHg group and the control group were scanned in 
alternating order. PET data were iteratively reconstructed (OSEM 2D, four itera-
tions) and corrected for decay, attenuation, scatter, and random coincidences. 
PET image analysis was performed using the Clinical Applications Packaging 
Program (CAPP5). The images were coregistered to an age-matched FDG 
template scan. Regions of interest (ROI) of cerebellum and hippocampus were 
drawn on the template FDG scan and transferred to the coregistered scan of the 
individual experimental animals. For each ROI, the radioactivity concentration 
was determined in Bq/cm3 and normalized for injected tracer dose and BW to 
obtain a standardized uptake value (SUV), which is defined as:
SUV= 




It is assumed that 1 cm3 of brain tissue equals 1 g.
Statistical analysis of the differences in [18F]FDG uptake in the individual 
brain regions between the MeHg group and the control group was performed 
with a two-sided, unpaired Student t-test. Differences between groups were 
considered statistically significant for p < 0.05.
Hippocampal slice preparation for extracellular field potentials. Rats of 
28 (± 3) and 65 (± 3) days old (Fig. 1) exposed to 0 (control group) or 1.5 mg/
kg MeHg were used for the analysis of the evoked local field potentials in hip-
pocampal brain slices. Animals were decapitated, and the brains were quickly 
removed. The whole brain was placed for approximately 1 min into cold (0ºC–









, 10mM D-glucose, and 
25mM NaHCO
3
 saturated with carbogen: 95% O
2
 and 5% CO
2
 to set the pH 
at 7.4) before dissecting the brain tissue that contained the hippocampus. The 
tissue block was glued on a vibratome (Leica VT 1000S, Wetzlar, Germany), 
and horizontal slices of 400 µm thickness were prepared that contained the 
hippocampus. The slices were transferred into a holding chamber containing 
ACSF at room temperature. After a 30-min recovery period, the slices were 
transferred to a holding chamber onto a LCR membrane filter (MilliPore mem-
brane filter, FHLC02500, PTFE hydrophilic membrane with 0.45 µm pore size; 
Millipore, Billerica, NA) placed on an ACSF-filled well, where they were kept 
at room temperature under a moistened carbogen atmosphere.
Extracellular recordings, electrical stimulation, and stimulation protocols.  
All recordings were performed at 31ºC in a submerged slice chamber with 
ACSF as the perfusion medium. Extracellular field potential recordings were 
performed with borosilicate glass micropipettes (2–4 MΩ) filled with ACSF. 
The extracellular recording electrodes were placed in the CA1 stratum pyrami-
dale (Fig. 3A1). Signals were amplified (1000×) with a custom-built amplifier 
and sampled at 5 kHz. Electrical stimulations were applied as a biphasic cur-
rent pulse of 200 μs through a bipolar stimulation electrode (isolated stain-
less steel wires of 60 μm thickness with the tips 50–100 μm separated) that 
was placed over the Schaffer collaterals in stratum radiatum at the CA1–CA3 
border (Fig. 3A1). The stimulation current for the threshold and the maximal 
response were determined for each slice individually, and the stimulus intensi-
ties were set using these two values as 0 and 100%, respectively. Two stimula-
tion protocols were used to quantify the synaptic and network properties of the 
CA1 network. First, stimulus-response curves were constructed using double 
pulse stimulation protocols with interpulse intervals of 20 ms at current intensi-
ties of 0, 5, 10, 15, 20, 30, 40, 50, 80, and 100%. The second protocol used a 
fixed intensity (10 or 80%) and varying interpulse intervals from 20 to 500 ms. 
The minimum interval between any stimulation was 8 s.
Extracellular field potential analyses. All responses were means of three 
realizations, and the mean field potentials were analyzed using custom-made 
software (Matlab, The MathWorks Inc., Natick, MA). A  local field potential 
recorded from the stratum pyramidale (Fig. 3A2) consists of the field equiva-
lents of the synaptic potential (field excitatory postsynaptic potential—fEPSP) 
and a superimposed population spike (PS). The amplitude of the latter was 
calculated as schematically indicated in Figure  3A2. The ratio (R) PS2/PS1 
was calculated to analyze the paired pulse interaction. One-way and three-
way ANOVAs were used for statistical evaluation of the data (Matlab, The 
MathWorks, Inc.).
Genome-wide gene expression profiling. Rats of 21 and 70  days old 
exposed to 0 (control group), 0.1, 0.4, 1.0, and 1.5 mg/kg MeHg were selected 
for microarray analysis of cerebellum and rats exposed to 0 and 1.5 mg/kg 
MeHg for cerebrum. Prior to isolation of total RNA, cerebral and cerebel-
lar brain regions were homogenized with a mortar and pestle under liquid 
nitrogen. Subsequently, the total RNAs derived from 3 to 6 biological rep-
licate samples per treatment group (total 47 cerebellum and 21 cerebrum 
samples) were isolated using the NucleoSpin RNA II kit (Macherey-Nagel, 
Düren, Germany) RNA purification kit. RNA samples (eluted in water) were 
stored at −80ºC before further processing. The isolated RNA samples were 
sent to ServiceXS BV (Leiden, The Netherlands) where they were processed 
according to Affymetrix protocols. In brief, RNA concentration was deter-
mined by absorbency at 260 nm with the Nanodrop ND-1000, and quality 
and integrity were verified using the RNA 6000 Nano assay on the Agilent 
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Next, 2  μg of 
high-quality total RNA was used with the Affymetrix Eukaryotic One-Cycle 
Target Labeling and Control reagents to generate Biotin-labeled antisense 
cRNA. The quality of the cRNA was checked using the Agilent 2100 bioana-
lyzer. The labeled cRNA was further used for the hybridization to Affymetrix 
Rat230-2.0 Genome Genechips, harboring 31099 probe sets. After an auto-
mated process of washing and staining, absolute values of expression were 
calculated from the scanned array using the Affymetrix Command Console 
v1 software.
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Microarray data preprocessing and quality control. Quality control 
microarray data were performed using simpleaffy and affyplm packages from 
the R/Bioconductor project through the Management and Analysis Database 
for MicroArray eXperiments (MADMAX) analysis pipeline, as previously 
described (Radonjic et al., 2009). Normalization of microarray data per tissue 
was performed through the same analysis pipeline using the library GC-RMA 
and employing the empirical Bayes approach for background correction fol-
lowed by quantile normalization. The custom MBNI CDF-file (CustomCDF_
rn230rnentrezg_v10.0.0), available  at http://brainarray.mbni.med.umich.edu/
Brainarray/Database/CustomCDF/CDF_download_v10.asp and http://nugo-r.
bioinformatics.nl/NuGO_R.html was used to reannotate the probes to new probe 
sets, remove poor quality probes, and derive unique signal values for different 
probe sets representing the same gene. This resulted in gene expression values 
for 11,498 genes with unique identifiers. Data were additionally filtered based on 
expression signals. To pass filtering criteria, gene expression was required to have 
a value above 5 in at least one of the experiments, resulting in 10,422 genes in 
cerebellum and 10,229 genes in cerebrum.
Statistical analysis of microarray data, pathway analysis, and 
visualization. Differentially expressed genes were identified using the limma 
package, applying linear models and moderated t-statistics that implement 
empirical Bayes regularization of standard errors (Smyth, 2004). The statistical 
analyses were performed through the Remote Analysis Computation for gene 
Expression data (RACE) suite at http://race.unil.ch (Psarros et  al., 2005). 
Doses of 0.1, 0.4, 1.0, and 1.5 mg/kg BW/day (GD6 to PND10) were tested 
on cerebellar gene expression. Gene expression under each MeHg dose 
treatment was compared with the control treatment (dose zero) per tissue 
and developmental stage (PND21 or PND70). To be statistically significant, 
fold change of gene expression was required to be either > 1.5 or < −1.5 and 
to have p value of < 0.01. The exception of the increasing dose effect (more 
differentially expressed genes with the increasing MeHg dose) at dose 1.5 mg/
kg at PND70 may be due to the maternal cannibalism that we observed in this 
particular treatment group, indicating that this dose was too high for optimal 
viability. The surviving animals within this group showed large heterogeneity 
(resulting in relatively poor statistical power) of their gene expression response.
Hierarchical clustering and visualization of gene expression changes 
were performed in GeneSpring GX 7.3.1 software (Agilent Technologies). 
The expression value of each gene was normalized to the mean value 
of that gene across all conditions. The average expression per treatment 
group is plotted. The analysis of up- or downregulated Gene Ontology 
categories (GO, www.geneontology.org) in cerebrum was performed using 
Toxprofiler based upon the T-profiler algorithm (Boorsma et al., 2005). As 
input values, average log
2
 ratio values of gene expression levels (MeHg 
treatment vs. control group) of all 10,229 genes were used. T scores were 
considered significant if E value (Bonferroni corrected) was smaller than 
0.05. This analysis results in T scores representing over-/underrepresenta-
tion of pathway-specific gene sets. Identification of overrepresented func-
tional categories among differentially expressed genes in cerebellum was 
performed using DAVID Functional Annotation Clustering tool (Dennis 
et al., 2003). The analysis was performed using regulated Gene Ontology, 
Protein domains, Pathways, and Functional categories according to the 
default settings. Representative statistically significant GO functional cat-
egories and genes belonging to these categories are manually selected and 
reported in Figure 5B.
rEsuLTs
Female Wistar rat pups were exposed to MeHg via mater-
nal diet during intrauterinal and lactational period from GD6 to 
PND10. The entire tested dose range was 0 (control treatment), 
0.1, 0.4, 0.7, 1, 1.5, and 2 mg/kg of MeHg. During weaning and 
adulthood, cerebellum and cerebrum were sampled for the analy-
sis by [18F]FDG PET functional imaging, field potential analysis, 
and microarray gene expression profiling (Fig. 1). As a reference 
for sensitivity assessment of these alternative assays, conven-
tional guideline tests for developmental neurotoxicity were 
also performed. In this article, a brief summary of the effects 
of MeHg found in the different conventional tests is given in 
Supplementary material. With exception of one parameter (i.e., 
sexual landmark “delayed vaginal opening”), none of the tests 
showed significant effect with NOAEL approach and a bench-
mark-advanced statistical method (Supplementary material).
Functional Imaging of Cerebellum and Hippocampus 
Suggests a Delay and Decrement in Brain Activity upon 
MeHg Exposure
As a surrogate biomarker for brain activity, glucose metabo-
lism was assessed in a longitudinal manner by [18F]FDG PET 
imaging at PND18, 22, 37, and 61. Cerebellum and hippocam-
pus of the control group and the rats exposed to MeHg at dose 
1.5 mg/kg were included in the analysis. Group comparison 
of [18F]FDG uptake in cerebellum and hippocampus between 
MeHg-treated and control rats did not reveal significant dif-
ferences at PND61. At PND18, however, [18F]FDG uptake in 
cerebellum (0.05 > p < 0.1) and hippocampus (0.05 > p < 0.1) 
tended to be lower in MeHg-treated animals than in controls. 
On day 22, however, [18F]FDG uptake in cerebellum (p < 0.05) 
and hippocampus (0.05 > p < 0.1) was (significantly) higher 
in MeHg-treated animals. On day 37, on the other hand, [18F]
FDG uptake was again significantly lower in the MeHg group 
than in controls both in cerebellum (p < 0.05) and hippocam-
pus (p  <  0.05). Strikingly, the pattern of [18F]FDG uptake 
over time was markedly different between both experimental 
groups, whereas within each group, cerebellum and hippocam-
pus showed similar uptake patterns (Fig. 2). As is illustrated in 
Figure 2, the FDG uptake apparently did not follow a gradual 
linear increase with age. In control animals, the average [18F]
FDG uptake in both hippocampus and cerebellum decreased 
between PND18 and 22 although not significantly. From 
PND22 to PND61, [18F]FDG uptake in both brain regions 
increased, which resulted in [18F]FDG uptake in both brain 
regions being significantly higher on PND61 than on either 
PND18 or PND22 (p < 0.05). In contrast, [18F]FDG uptake in 
both hippocampus and cerebellum of MeHg-treated animals 
increased between day 18 and 22, then decreased between day 
22 and 37, and increased again between day 37 and 61. None of 
these differences in tracer uptake between different days were 
statistically significant, except for the difference in [18F]FDG 
uptake in hippocampus between PND18 and 22 (p  <  0.05). 
At PND22 and PND37, the [18F]FDG uptake levels of MeHg-
exposed animals were similar to the ones of control animals at 
PND18 and PND22, respectively. These results might be sug-
gestive for a possible delayed phase-shift pattern as depicted 
in Figure  2 by the artificial “15  days shift” graph, resulting 
from shifting the “dip” in [18F]FDG uptake in the MeHg curve 
(PND37) toward the “dip” in the curve of the control group 
(PND22). It should be borne in mind, however, that [18F]FDG 
uptake was measured only at four test ages. Brain activity in 
between the four measured time points is not known.
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MeHg Exposure Modifies Neurotransmission in the 
Hippocampus Assessed In Vitro Using Field Potentials
Basic neurotransmission was assessed in the pyramidal cell 
layer of the hippocampal CA1 region using field potential record-
ings in acute brain slices. The slices were obtained from control 
and MeHg-exposed rats (dose 1.5 mg/kg) at time points PND28 
and PND68. In each group, a total of five rats were tested, com-
ing from separate litters. From each rat, the field potentials were 
recorded in two brain slices, one from the left and one from the 
right hemisphere. The field potential amplitudes were defined 
per slice, and the data were averaged over hemispheres and 
rats. Stimulation of the afferent Schaffer collaterals (Fig. 3A1) 
induces a field potential in stratum pyramidale that consists of a 
representation of the synaptic currents (fEPSP) and a superim-
posed synchronized action potential (the PS, Fig. 3A2) evoked 
in the pyramidal neurons (Fig. 3A1). Stronger stimulation leads 
to a PS of larger amplitude; Figure 3B gives a typical result 
for the PND28. The threshold and the maximum stimulation 
intensity were set for each slice. The currents required to reach 
a threshold and to evoke a maximum field potential were not 
significantly different between the control and MeHg-exposed 
group at 28 and 68 days. The relation between PS amplitude 
and stimulus intensity is also observed in the MeHg-exposed 
group. Comparable stimulus response relations were obtained 
for the PND68 (data not shown). However, the maximum PS 
was significantly smaller at PND68 than at PND28 (p < 0.01).
Applying a second stimulus shortly after the first one reveals 
the short-term dynamics of the activated synapses. The PS2/PS1 
ratio was determined for each stimulus pair given (Fig.  3A2). 
A  ratio < 1 indicates paired pulse depression, and a ratio > 1 
indicates paired pulse facilitation. Although the mean amplitudes 
of the PS1 and PS2 are not different (Fig. 3B), the short-term 
dynamics of the network do show effects of age and maternal 
MeHg exposure (Fig.  3C). The PND68 control group shows 
facilitation, primarily at the lower stimulus intensities, which was 
FiG. 2. Standardized [18F]FDG brain uptake value (SUV) in cerebellum (A) and 
hippocampus (B) in rats exposed to 1.5 mg/kg of MeHg (black filled circles) and in 
control animals (open circles). Over time, [18F]FDG brain uptake seemed to follow 
a typical pattern in both groups but different in time. High activity around day 18 in 
the control group can be explained by the fact that the animals are very active at this 
time point (comparable with high activity generally observed at this age in rats of this 
Wistar strain during MAA). Noticed that the [18F]FDG uptake levels at the “dip” of 
the curves—PND37 in the MeHg group and PND22 in the control group—do not 
differ. The curve of [18F]FDG uptake in MeHg animals was shifted 15 days—moving 
the “dip” at PND37 toward the “dip” at PND22 of the control group—suggesting 
delayed brain development in MeHg-treated animals (grey filled circles, dotted line).
FiG. 1. Experimental design. Female Wistar rat pups were exposed to MeHg via maternal diet during intrauterine and lactation period (from GD 6 to PND10). 
During weaning and adulthood, cerebellum and cerebrum were studied and analyzed by [18F]FDG PET functional imaging in vivo, ex vivo/in vitro field potential 
analysis, and ex vivo microarray gene expression profiling. This figure can be viewed in color online.
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not observed in the PND28 control group (ANOVA, main effect 
of age: F = 145.5; p < 0.01; interaction age × stimulus intensity: 
F = 5.62; p < 0.01). In the MeHg-exposed group, at PND28, the 
PS2/PS1 ratio was changed into a small paired pulse depression, 
whereas at PND68, the group showed an enhanced paired pulse 
facilitation (ANOVA: main effect of MeHg exposure: F = 4.43; 
p < 0.05; interaction age × MeHg exposure: F = 17.1; p < 0.01).
The interval between the two stimuli is an important param-
eter that elucidates the underlying mechanisms. We system-
atically varied the interpulse interval between 20 and 500 ms 
and kept the stimulus intensity fixed at 80% to ensure action 
potential firing in response to the first pulse. In the control 
and the MeHg-exposed groups, only a very small facilita-
tion was observed at PND28, which gradually vanished for 
FiG. 3. (A1) A schematic drawing of the CA3 and CA1 region of the hippocampus of the rat. The triangles represent the cell bodies of the pyramidal cells (p), neatly 
aligned in the stratum pyramidale (pyr). The dendrites of the pyramidal cells are found in the stratum radiatum (rad) and the stratum lacunosum moleculare (slm). The 
Schaffer collaterals (Sch), axons of the CA3 pyramidal cells, project to the dendrites of the CA1 pyramidal cells. The axons of the CA1 pyramidal cells to inhibitory 
interneurons (i) within the CA1. These inhibitory interneurons project to the CA1 pyramidal cells in turn (feedback inhibition). The bipolar stimulation electrode was 
placed in parallel to the Schaffer collateral. The local field potentials were recorded in the stratum pyramidale. (A2) Local field potential recorded in the stratum pyramidale 
after double pulse stimulation of the Schaffer collaterals. The arrowheads (Stim1 and Stim2) indicate the moments of stimulation. The recording shows the extracellular 
representation of the field excitatory postsynaptic potential (fEPSP in blue; only indicated for Stim2) and the superimposed sharp negative deflection of the population 
spike (PS1 and PS2 in red); the determination of the PS amplitude is schematically explained. (B) Stimulus-response relations for the PS amplitude recorded in the stra-
tum pyramidale of CA1 in response to Schaffer collaterals stimulation in hippocampal slices of PND28. Two stimuli, 20 ms apart, with the same stimulus intensity were 
applied; the intensity was stepwise increased from 0% (threshold for response) until 100% (saturation of response). Triangles represent the PS amplitude in response to 
the first stimulus (pulse 1); circles represent the PS amplitude in response to the second stimulus (pulse 2). The open symbols (in light and dark blue colors) represent 
the control group; the closed symbols (in pink and red colors) represent the MeHg-exposed group. The lines represent the mean data for each group (n = 10 [5 animals 
per group; left and right brain hemisphere/animal]); vertical bars represent SEM. (C) PS2/PS1 ratio as a function of stimulus intensity. The interpulse interval is 20 ms. 
Triangles represent PND 28, and circles represent PND 68. The open symbols (in light and darker blue) represent the control group, and the closed symbols (in pink and 
red) represent the MeHg-exposed group. The lines represent the mean data for each group (n = 10 [5 animals per group; left and right brain hemisphere/animal]); vertical 
bars represent SEM. (D) PS2/PS1 ratio as a function of stimulus interval for a fixed stimulus intensity of 80%. The markers and line colors are as in (C). The lines represent 
the mean data for each group (n = 10 [5 animals per group; left and right brain hemisphere/animal]); vertical bars represent SEM. This figure can be viewed in color online.
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longer intervals and was not different between the two groups 
(Fig. 3C). At PND68, the facilitation in controls is larger than 
at PND28, and in the MeHg-exposed group, it is even larger 
(Fig. 3D) than in controls. A gradual decline of the facilita-
tion was observed as a function of the time interval between 
P2 and P1 (Fig. 3D), (ANOVA main effect MeHg: F = 5.13; 
p  <  0.05; main effect age: F  =  21.98; p  <  0.01; interaction 
MeHg × age: F = 6.76; p < 0.01). The same interpulse inter-
val experiment was repeated at a stimulus intensity of 10%. In 
this case, there will be no action potential firing in response 
to the first pulse, and no feedback inhibitory interneurons will 
be recruited (Fig. 3A1). The facilitation of the fEPSP in the 
PND68 MeHg was higher compared with the facilitation in 
the PND68 control group (data not shown), similar to the 80% 
interpulse interval experiment.
Transcriptional Profiling Reveals a Phase Shift in Gene 
Expression of MeHg-Exposed Rats Compared with the 
Control Animals
To identify molecular mechanisms underlying effects of 
MeHg on rat brain development, cerebellar and cerebral RNA 
extracts at weaning (PND21) and adulthood (PND70) of the 
control and MeHg-exposed rat pups were subjected to micro-
array gene expression profiling using Affymetrix Rat 230-2.0 
Chips. Cerebellar effects were investigated at MeHg dose range 
of 0 (control), 0.1, 0.4, 1, and 1.5 mg/kg. The investigated dose 
for cerebrum was limited to 0 and 1.5 mg/kg. In total, 10,422 
and 10,229 genes were identified as expressed in cerebellum 
and cerebrum, respectively.
The analysis of differentially expressed genes (p value < 0.01 
and absolute fold change > 1.5) reveals that MeHg affects 
larger number of genes at PND70 than at PND21 (Table  1). 
The annotated list of cerebellar and cerebral differentially 
expressed genes and their expression ratios compared with the 
control treatment is provided in Supplementary material. With 
the exception of the highest MeHg dose (1.5 mg/kg), the num-
ber of genes called significant in cerebellum increases with the 
exposure dose. To compare intensities of the gene expression 
changes across all conditions, differentially expressed genes in 
cerebellum and cerebrum were normalized to the mean value 
per gene and subjected to hierarchical clustering (Figs. 4A 
and B, respectively). This shows that in the control condition, 
there are many genes that are differentially expressed between 
the two developmental time points (PND21 and PND70). In 
animals exposed to MeHg at doses 1 and 1.5 mg/kg, cerebellar 
genes that are highly expressed at PND21 and lowly expressed 
at PND70 in the control condition are lowly expressed at PND21 
and highly expressed at PND70 in MeHg-treated groups and 
vice versa. Such expression profiles of these genes thus appear 
phase shifted compared with the control groups. This suggested 
deregulation of appropriate timing of the neural gene expres-
sion program upon MeHg exposure resembles the suggestive 
MeHg-induced phase-shift pattern of the glucose uptake rate 
observed by [18F]FDG PET imaging.
Molecular Mechanisms Underlying the MeHg Effects on 
Neurodevelopment
To identify molecular processes that are possibly affected 
by MeHg exposure in developing rat brains, differentially 
expressed genes in cerebrum and cerebellum were subjected 
to pathway analyses. The results reveal that many of MeHg 
affected genes are involved in nervous system development, 
including both structural and functional aspects (Figs. 5A 
and B). In cerebrum, all GO categories related to neurodevel-
opmental processes are downregulated (Fig. 5A). Specifically, 
pathways related to structural aspects of brain development 
(e.g., nervous system development, ensheathment of neurons, 
myelination, cytoskeleton organization, and biogenesis) are 
significantly repressed at PND21, whereas PND70 is predomi-
nantly characterized by significant repression of pathways 
related to synaptic transmission and brain function (synaptic 
vesicle, transmission of nerve impulse, behavior). The analysis 
of overrepresented GO categories in cerebellum revealed that 
also in this brain part, MeHg significantly affects processes 
related to neural function and development, such as synaptic 
transmission, neuron projection, transmission of nerve impulse, 
dorsal/ventral pattern formation, and nervous system develop-
ment (Fig. 5B).
Detailed examination of genes affected by MeHg cerebel-
lum reveals expression changes in many developmental regu-
lators (Foxg1, Ctxn [cortexin], Gda, Ptms, Akt, Basp, Lhx2, 
Arsb), developmental phase–associated genes (Cxxc4, St18, 
Atrx, Bmpr1c, Fut9, Kif1b, Mtap2, and PPARgC1b) and genes 
involved in small GTPase signaling pathways regulating cell 
growth and proliferation (Supplementary material). Apart from 
the structural aspects, representatives of all processes required 
for synaptic transmission are identified as significantly 
affected by MeHg. This includes neurotransmitters (Cck [chol-
ecystokinin], Pmch, Pcsk1n), neurotransmitter synthesis gene 
(Gad2), neurotransmitter receptors (Cnr1 [cannabinoid recep-
tor 1], Gabrb3 [GABA
A
 receptor], and LOC289606 [GABA
A
 
receptor homolog]), synaptic vesicle docking/transport/neu-
rotransmitter secretion genes (Spt5, Syn1a, Cplx2, Myo5a, 
Slc6a6, Lin7c, Lin7a, Exoc8), voltage-gated Ca2+ channels 
(Cacnb4, Ryr3, LOC689560), Ca2+/calmodulin binding pro-
teins and kinases (Camkk2, Camk2n1, Camk4, Marcksl1), 
and regulators of synaptic plasticity (Nrgn [neurogranin], 
Ddn [dendrin], and Rnf39). Particularly marked repression of 
several genes regulating brain development (Foxg1, Gda) and 
TabLE 1  
Number of significantly Differentially Expressed Genes upon 
MeHg Exposure at PND 21 and 70
Cerebellum Cerebrum
MeHg (mg/kg) 0.1 0.4 1 1.5 1.5
PND21 6 7 8 18 11
PND70 22 23 115 34 14
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function (Cck and Nrgr, long-term potentiation and learning 
regulator) is observed at PND70, showing that pre-/perinatal 
MeHg exposure has distinct long-term effects on brain struc-
ture and function. In addition to effects on neural structure 
and function, a number of differentially expressed genes point 
to effects of MeHg on the brain immune system (Nrgn, Akt1, 
Adam10, Myo5a).
Together, microarray gene expression profiling corroborates 
findings regarding delay and decrement in brain function and 
compromised functionality of neurotransmission discovered by 
[18F]FDG PET imaging and field potential analysis and identi-
fies key regulators of these processes.
DiscussioN
In the study presented here, maternal exposure to MeHg was 
studied in rat offspring using [18F]FDG PET functional imaging, 
field potential analysis, and microarray gene expression profil-
ing. For PET and field potential analyses, a dosage of 1.5 mg 
MeHg/kg BW/day (GD6-LD10) was used; for gene expression 
profiling, low dosages of 0.1, 0.4, and 1.0 mg MeHg/kg were 
studied in addition.
MeHg is a well established neurotoxin both in humans and 
animals. The developing brain appears more vulnerable to the 
toxic effects of MeHg than the adult, and much lower dos-
ages are required to generate deleterious effects (Costa et al., 
2004; Franco et  al., 2006; Grandjean and Landrigan, 2006; 
Kjellstrom et  al., 1989; Manfroi et  al., 2004). Humans are 
exposed to MeHg, for example, through the consumption of 
fish and shellfish. After absorption through the digestive tract, 
MeHg can penetrate the blood-brain barrier and the placenta 
(Choi, 1989; Clarkson and Magos, 2006). Because of its long 
half life in the human body, it accumulates in the brain where 
it causes damage to the central nervous system (Coccini, 2000; 
Spyker, 1972). MeHg has been studied extensively, and adverse 
effects on brain development and animal behavior (func-
tional) have been found (Weiss, 2005). Structural damage to 
the developing brain is diffuse, whereas damage is restricted 
FiG. 4. (A) A heat map showing expression of genes differentially expressed in cerebellum under at least one of the time points and doses of MeHg compared 
with the control condition (0 mg/kg) (n = 159). The expression value of each gene was normalized to the mean value of that gene across all conditions. The average 
expression per treatment group is plotted. (B) Similar to (A) for genes differentially expressed in cerebrum under MeHg dose 1.5 mg/kg compared with the control 
condition (dose 0 mg/kg) (n = 25). This figure can be viewed in color online.
8 RADONJIC ET AL.






FiG. 5. (A) The selected GO functional categories significantly downregulated (negative T values) in cerebrums of MeHg-exposed rats at PND21 and PND70. 
Pathways related to brain structure are mostly affected at PND21, whereas pathways related to brain function are affected at PND70. The Bonferroni corrected E 
value < 0.05 is at |T| > 4. (B) The selected GO functional categories significantly overrepresented among 159 genes differentially expressed in cerebellum under 
at least one of the doses of MeHg compared with the control condition.
 EFFECT OF MeHg ON DEVELOPING RAT BRAIN 9






to cerebellum and visual cortex in the adult brain (Burbacher 
et  al., 1990). Prenatal exposure is related to abnormal neu-
ronal migration and deranged cerebral cortical organization. 
Children exposed to MeHg may be mentally retarded and show 
decreased IQ, impaired movements, visuospatial perception, 
and speech (Castoldi et  al., 2008; Harada, 1995; Grandjean 
et al., 1997; Kjellstrom et al., 1989). Effects on animal behav-
ior include, among others, reduced motor activity (Björklund, 
2007), a decrease in memory ability (Carratù et al., 2006; Daré 
et al., 2003; Sakamoto, 2002) and learning (Paletz et al., 2006). 
Mechanisms underlying mercury-induced neurotoxicity have 
been focused on for many years. To mention, disruption of cal-
cium homeostasis or induction of oxidative stress via overpro-
duction of reactive oxygen species or reduction of antioxidative 
defenses is likely to be critical factors in MeHg-induced cell 
damage, as are interactions with sulfhydryl groups (Ceccatelli 
et al., 2010; Farina et al., 2011a, b; Giordano and Costa, 2012). 
Yet, the molecular mechanisms mediating MeHg-induced neu-
rotoxicity are not completely understood.
In this study, we investigated mechanisms underlying neu-
rodevelopmental defects associated with maternal exposure to 
MeHg. [18F]FDG PET functional imaging of cerebellum and 
hippocampus, the analysis of functional neurotransmission in 
the hippocampus, and microarray gene expression profiling of 
cerebrum and cerebellum were employed to assess the effects 
of MeHg exposure on structure and function of rat brains in 
juvenile and adult stages of development. The rat has been 
reported to be a good model to study developmental neurotox-
icity of MeHg (Costa et al., 2011; Giordano and Costa, 2012).
We find that MeHg causes structural defects and delay and 
decrement in (onset of) neural activity in both cerebrum and 
cerebellum of Wistar rat pups. Importantly, although the pups 
were exposed to MeHg early in developmental stage (from GD6 
to PND10, i.e., lactation) and the mercury levels in the brain 
already returned to control level on PND21 (data not shown), 
the significant effect on neural structure and function persisted 
into adulthood (PND70) on a functional and molecular level.
The development of the brain is a highly complex process 
in which timing of events is crucial to ensure that development 
proceeds normally (Mai and Ashwell, 2004). One of the main 
observations in this study is that this timing is disrupted in ani-
mals exposed to MeHg in both cerebrum and cerebellum. This 
is evident from the gene expression profiling, which shows that 
the specific timing of transcriptional programs associated with 
early and late developmental stage is disturbed in MeHg-treated 
groups. Genes that are required to be highly expressed at early 
stage and lowly expressed at the late stage in the control condi-
tion show an opposite pattern of expression in MeHg-treated 
groups. Indeed, many of such genes with phase shift in timing 
of expression are described as developmental phase–associated 
genes. [18F]FDG PET imaging data appear to be in agreement 
with gene expression findings, as PET imaging results also 
seem to concur with a delayed glucose consumption pattern in 
hippocampus and cerebellum of MeHg-exposed animals. The 
peak in [18F]FDG uptake observed in the control group around 
day 18 can be explained by the fact that rats of this Wistar strain 
are very active at this time point as is generally seen during 
MAA where activity at PND17 is larger than that measured 
at PND21. In the hippocampus of the MeHg group, [18F]FDG 
uptake significantly increased between PND18 and PND22. 
The fact that this peak in brain activity—[18F]FDG uptake—is 
found at a later time point in the MeHg group (PND22) where 
the activity in the control group is already going down (as in 
MAA) supports the suggestive neurodevelopmental delay 
depicted in the “15  days shift” in Figure  2. Clearly, a neu-
rodevelopmental delay of 15 days early in life does not seem 
realistic. Most likely, MeHg interfered with neurodevelopmen-
tal processes at a critical time window of brain development 
inducing a small delay, which may even go unrecognized. 
Yet, neurodevelopment may increasingly lag behind with age, 
becoming apparent later in life during adulthood or senescence 
(Grandjean and Herz, 2011). Together, these results and gene 
expression findings suggest that MeHg induces a delay in onset 
of brain development and function both in cerebellum and 
cerebrum.
The assessment of MeHg effects at two time points allows 
us to discriminate between early (weaning) and late (adult-
hood) neurodevelopmental defects caused by pre-/perina-
tal exposure to MeHg. Surprisingly, the effect of MeHg is 
amplified and persisting at the adult stage, despite the fact 
that MeHg has been eliminated from the system long time 
ago. This is manifested by a higher number of differentially 
expressed genes at PND70 compared with PND21, persist-
ing lower glucose uptake rate (also) at PND61 and increase in 
potentiation of hippocampal neurons specifically at PND68. In 
the cerebrum, phase-specific MeHg effects are evident from 
pathway analyses of differentially expressed genes. Pathways 
related to structural aspects of brain development are signifi-
cantly repressed at PND21, whereas PND70 is predominantly 
characterized by significant repression of pathways related to 
synaptic transmission. This suggests that pre- and perinatal 
MeHg exposure at first instance causes impaired development 
of morphological features of the brain, which is in line with a 
previous report on significant neuron loss at PND21 (de Groot, 
personal communication), whereas at the adult stage, MeHg-
caused impairment in cerebrum is mostly apparent in brain 
function disorders.
Functional changes at the adult stage by MeHg are also 
shown by the analysis of neurotransmission in hippocampus. 
The extracellular field potential recordings in the hippocampus 
provide a marker for synaptic transmission, and double pulse 
stimulation can elucidate some characteristics of the under-
lying mechanisms. MeHg exposure causes increased paired 
pulse facilitation at PND68, which is generally explained by 
an increase in neurotransmitter vesicle release. This increase 
could have several underlying causes, but one of the most com-
mon explanations at lower stimulus intensities (Fig.  3C) and 
one that is expected to gradually decline with stimulus interval 
10 RADONJIC ET AL.






(Fig. 3D) is the residual calcium hypothesis (Katz and Miledi, 
1968; Miledi and Thies, 1971; Parnas et  al., 1982; Zucker, 
1989). Additionally, network properties could also contribute 
to the change in vesicle release because activation of pyramidal 
cells leads to activation of feedback inhibition of the GABA-
ergic interneurons (Fig. 3A1), which could in turn inhibit the 
second PS in the double pulse protocol (Stanford et al., 1995). 
However, at PND68, there is a strong paired pulse enhance-
ment with an interval dependency that strongly suggests that 
the residual calcium is underlying it.
One of the most prominently differentially expressed genes 
under MeHg treatment is Neurogranin (Nrgn), regulator of syn-
aptic plasticity (Díez-Guerra, 2010; Prichard et al., 1999). Nrgn 
is significantly repressed in cerebellum at both PND21 and 
PND70, even at doses as low as 0.4 and 0.1 mg/kg MeHg, sug-
gesting that this factor may be responsible for regulating MeHg-
induced functional impairment. Another severely repressed 
gene in cerebellum is Foxg1 (−8.3-fold downregulation at dose 
1 mg/kg at PND70). FOXG1, also known as Brain factor 1, has 
been found to play an important role in the establishment of the 
regional subdivision of the developing brain and in the devel-
opment of the telencephalon (Tao and Lai, 1992). In addition, 
Foxg1 mutations are associated with the neurodevelopmental 
disease Rett syndrome. Considering its severe repression upon 
MeHg exposure, it is plausible that this factor may be important 
for regulating MeHg-mediated structural defects.
Finally, in our study, the effects of MeHg observed by [18F]
FDG microPET functional imaging, functional neurotrans-
mission analysis, and microarray gene expression profiling 
were not identified by classical methods included in current 
guidelines for neurotoxicity testing. Such improved sensitiv-
ity of detection of relevant neurotoxic effects implies that the 
current testing protocols for neurotoxicity could be enhanced 
by employment of innovative methods in addition (or as an 
alternative) to conventional guideline endpoints. This may 
have important implications on juvenile health care but also 
on improvement of procedures for animal testing, such as 
increased efficiency and sensitivity and decrease of number of 
animals used, time, and costs of testing.
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